GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » PS Ratio

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) PS Ratio : (As of May. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zynerba Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zynerba Pharmaceuticals's share price is $1.30. Zynerba Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00. Hence, Zynerba Pharmaceuticals's PS Ratio for today is .

The historical rank and industry rank for Zynerba Pharmaceuticals's PS Ratio or its related term are showing as below:

During the past 10 years, Zynerba Pharmaceuticals's highest PS Ratio was 25190.00. The lowest was 60.00. And the median was 844.00.

ZYNE's PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.21
* Ranked among companies with meaningful PS Ratio only.

Zynerba Pharmaceuticals's Revenue per Sharefor the three months ended in Jun. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

During the past 10 years, Zynerba Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was -54.30% per year. The lowest was -81.80% per year. And the median was -68.05% per year.

Back to Basics: PS Ratio


Zynerba Pharmaceuticals PS Ratio Historical Data

The historical data trend for Zynerba Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynerba Pharmaceuticals PS Ratio Chart

Zynerba Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 495.00 - - - -

Zynerba Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zynerba Pharmaceuticals's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Zynerba Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zynerba Pharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zynerba Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Zynerba Pharmaceuticals's PS Ratio falls into.



Zynerba Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Zynerba Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.30/0
=

Zynerba Pharmaceuticals's Share Price of today is $1.30.
Zynerba Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Zynerba Pharmaceuticals  (NAS:ZYNE) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Zynerba Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Zynerba Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333
Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Executives
Kenneth T Jones officer: See Remarks C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Brian Rosenberger officer: VP, Commercial & Business Dev. C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Terri B Sebree officer: President ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
James E Fickenscher officer: Chief Financial Officer C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087
Armando Anido director, officer: Chairman & Chief Exec. Officer 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Kenneth I Moch director 68 WILLOW AVE, LARCHMONT NY 10538
Warren D Cooper director NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577
Pamela Stephenson director C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
William J Federici director 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Albert P Parker officer: Chief Legal Officer C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Suzanne M. Hanlon officer: Sec, General Counsel & VP HR 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Michael Rapp 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Thomas L Harrison director

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Headlines

From GuruFocus